Article
Diet and breast cancer in causation and therapy
Article first published online: 29 JUN 2006
DOI: 10.1002/1097-0142(19861015)58:8+<1804::AID-CNCR2820581404>3.0.CO;2-N
Copyright © 1986 American Cancer Society
Issue
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470)
Cancer
Supplement: American Cancer Society Second National Conference on Diet, Nutition, and Cancer
Volume 58, Issue Supplement S8, pages 1804–1813, 15 October 1986
Additional Information
How to Cite
Wynder, E. L., Rose, D. P. and Cohen, L. A. (1986), Diet and breast cancer in causation and therapy. Cancer, 58: 1804–1813. doi: 10.1002/1097-0142(19861015)58:8+<1804::AID-CNCR2820581404>3.0.CO;2-N
Publication History
- Issue published online: 29 JUN 2006
- Article first published online: 29 JUN 2006
- Manuscript Accepted: 19 FEB 1986
Funded by
- PHS. Grant Numbers: CA-17613, CA-29602, CA-32617
- Abstract
- References
- Cited By
Abstract
The major macronutrient associated with increased breast cancer risk is dietary fat. Evidence for this association is based on epidemiologic, clinical, and laboratory animal studies. In addition, there is suggestive epidemiologic evidence that differences in postmastectomy survival rates in Japan and the United States may be attributable to differences in dietary fat intake. The importance of the type of fat consumed, as well as its amount, has emerged as an issue of major importance. Some oils, including those rich in monounsaturates, medium chain fatty acids, or omega-3 (n-3) fatty acids appear to lack tumor-promoting effects despite their presence in the diet at high levels. Possible mechanisms by which dietary fat may exert its effects could be either direct or indirect. Direct mechanisms involve dietary modification of membrane structure and function; indirect mechanisms involve alterations in the endocrine system, and/ or the metabolism of essential fatty acids to biologically active eicosanoids such as prostaglandins, and suppression of immune responses. Dietary guidelines and dietary intervention trials for the primary and secondary prevention of breast cancer are discussed.

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)